Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age

BACKGROUND: A dose-sparing inactivated polio vaccine (IPV-Al), obtained by adsorption of inactivated virus to an aluminium hydroxide adjuvant, can help mitigate global supply and the cost constraints of IPV. The objective of this trial was to demonstrate the non-inferiority of IPV-Al to standard IPV...

Descripción completa

Detalles Bibliográficos
Autores principales: Bravo, Lulu C., Carlos, Josefina C., Gatchalian, Salvacion R., Montellano, May Emmeline B., Tabora, Charissa Fay Corazon B., Thierry-Carstensen, Birgit, Tingskov, Pernille Nyholm, Sørensen, Charlotte, Wachmann, Henrik, Bandyopadhyay, Ananda S., Nielsen, Pernille Ingemann, Kusk, Mie Vestergaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983932/
https://www.ncbi.nlm.nih.gov/pubmed/31703934
http://dx.doi.org/10.1016/j.vaccine.2019.10.064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983932/
https://www.ncbi.nlm.nih.gov/pubmed/31703934
http://dx.doi.org/10.1016/j.vaccine.2019.10.064

Ejemplares similares